Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 23, 2025

Warren Buffett: This asset offers ‘more opportunity’ than real estate, young Charlie Munger would pick it ‘in a second’

View original at finance.yahoo.com
Warren Buffett: This asset offers ‘more opportunity’ than real estate, young Charlie Munger would pick it ‘in a second’ Getty/JOHANNES EISELE Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stock market offers more opportunity than real estate in the United States

    80% confidence

  • Would buy 1% of all apartment houses in the country for $25 billion

    80% confidence

  • Real estate negotiations take forever and begin when you agree on deals

    80% confidence

  • Real estate trouble often involves dealing with more than equity holders

    80% confidence

  • For most people, the best investment is owning the S&P 500 index fund

    80% confidence

  • Renters sometimes don't pay due to cancer, car wrecks, job loss, or pandemics

    80% confidence

  • Real estate deals are more complex and time-consuming than stock transactions

    80% confidence

  • Stock transactions can be done quickly and anonymously at New York Stock Exchange

    80% confidence

  • Young Charlie Munger would have chosen stocks over real estate if forced to pick one for life

    80% confidence

  • At age 94, getting involved in lengthy real estate negotiations is not interesting

    80% confidence

  • It's a ridiculous assumption that renters are going to make the payments for landlords

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Warren Buffett: This asset offers ‘more opportunity’ than real estate, young Charlie Munger would pick it ‘in a second’ — Source | Via News | ViaNews EU